Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

BioMarin Pharma. News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN Branche:  Biotechnologie Land:  USA
54,65 $
+0,54 $
+1,00%
46,456 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
9,78 Mrd. €
Streubesitz
1,13%
KGV
16,80
Index-Zuordnung
Nasdaq Composite Index
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,29: MM5QHK
Werbung

BioMarin Pharmaceutical News

12.03.26 - PR Newswire
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 ...
27.02.26 - PR Newswire
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-​pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) PR Newswire
24.02.26 - PR Newswire
BioMarin to Participate in Four Upcoming Investor Conferences in March
BioMarin to Participate in Four Upcoming Investor Conferences in March PR Newswire
23.02.26 - PR Newswire
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results PR Newswire
17.02.26 - PR Newswire
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET PR Newswire
12.02.26 - PR Newswire
BioMarin Announces Closing of Private Offering of Senior Notes
BioMarin Announces Closing of Private Offering of Senior Notes PR Newswire
29.01.26 - PR Newswire
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility PR Newswire
26.01.26 - PR Newswire
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility PR Newswire
13.01.26 Wirtschaftswoche
BörsenTag: So teuer sind die Rüstungsaktien
Die schwierigste aller Börsenfragen: Soll ich dem Trend folgen, bis zum Ende und darüber hinaus – oder konträr handeln und ungeliebte Papiere kaufen? Überlegungen zu TKMS, ...
12.01.26 - PR Newswire
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
BioMarin Appoints Arpit Davé Chief Digital and Information Officer PR Newswire
09.01.26 - PR Newswire
Veeva und BioMarin schließen langfristige strategische Partnerschaft
Veeva und BioMarin schließen langfristige strategische Partnerschaft PR Newswire
08.01.26 - PR Newswire
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA PR Newswire
08.01.26 - PR Newswire
Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva and BioMarin Form Long-Term Strategic Partnership PR Newswire
08.01.26 - PR Newswire
Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva and BioMarin Form Long-Term Strategic Partnership PR Newswire
19.12.25 - PR Newswire
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook PR ...
11.11.25 - PR Newswire
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England PR Newswire
29.10.25 - PR Newswire
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-​pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with ...
27.10.25 - PR Newswire
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update PR Newswire
22.10.25 - PR Newswire
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET PR Newswire
08.09.25 - PR Newswire
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »